Comparing MRI and PET scans for liver cancer diagnosis
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
NA · University of Aarhus · NCT05359939
This study tests whether MRI or two types of PET scans are better at finding small liver cancer spots in patients with liver cirrhosis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Aarhus (other) |
| Locations | 1 site (Aarhus) |
| Trial ID | NCT05359939 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of MRI and two types of PET scans (using 18F-FDGal and 18F-choline) in diagnosing hepatocellular carcinoma (HCC), a common and aggressive liver cancer. The research aims to determine which imaging technique provides better sensitivity for detecting small lesions in patients with HCC, particularly those with underlying liver cirrhosis. By evaluating these imaging modalities, the study seeks to improve diagnostic accuracy and patient outcomes in HCC management.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with hepatocellular carcinoma.
Not a fit: Patients who have contraindications for MRI or PET scans, such as severe renal insufficiency or claustrophobia, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and earlier diagnosis of hepatocellular carcinoma, potentially improving treatment outcomes for patients.
How similar studies have performed: Previous studies have shown promising results in using advanced imaging techniques for cancer diagnosis, suggesting that this approach may yield beneficial outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with hepatocellular carcinoma * age above 18 years Exclusion Criteria: * the patient does not want to take part in the study * the responsible investigator determines that the patient is not qualified for a PET scan * a history of moderate or intense hypersensitivity to a gadolinium-based contrast agent * renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m2 body surface area * contraindications for MRI including claustrophobia * pregnant or nursing patients.
Where this trial is running
Aarhus
- Aarhus University Hospital — Aarhus, Denmark (RECRUITING)
Study contacts
- Study coordinator: Mona Kristiansen, MD
- Email: mkk@clin.au.dk
- Phone: +4527491598
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma